相关实验视频

Updated: Jul 11, 2026

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

三级淋巴细胞结构预测了肺状细胞癌的预后和免疫检查点抑制剂的有效性

Kuifei Chen^1,2, Suna Zhou², Pin Zhou³

¹Taizhou Hospital of Zhejiang Province, Shaoxing University, Taizhou, Zhejiang, China.

|August 15, 2025

概括

三级淋巴细胞结构 (TLSs) 的存在,高密度和成熟度与肺状细胞癌 (LUSC) 的更好的结果有关. 这些发现强调了TLS作为LUSC患者的积极预后因素,可能预测免疫疗法反应.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
病理学病理学病理学

背景情况:

肺状细胞癌 (LUSC) 是一个重大的死亡率挑战.
三级淋巴体结构 (TLS) 是关键的微环境组件,调节抗瘤免疫反应.

研究的目的:

为了研究TLS在LUSC的预后影响.
评估TLS对LUSC患者免疫治疗疗效的预测价值.

主要方法:

血素和欧染色和免疫光染色被用于评估TLS.
对根据TLS存在,密度和成熟度分层的患者进行了比较生存分析 (imTLS与mTLS).
多变量考克斯回归模型分析了LUSC免疫治疗队列中的预后因素.

主要成果:

TLS存在 (TLS+) 和高TLS密度与更好的整体存活率 (OS) 有显著的关联.
成熟的TLS (mTLS) 在LUSC患者中显示出与改善的OS有很强的相关性.
阶段和高PD-L1表达 (≥50%) 被确定为TLS+状态的预测因素.

结论:

TLSs,特别是当存在于高密度和成熟状态时,代表了LUSC的有利预后因素.
在LUSC免疫疗法队列中,TLS状态是整体生存的独立预测指标.
TLS评估可能有助于预测LUSC患者的预后和免疫治疗反应.

关键词:

免疫疗法免疫疗法肺状细胞癌是肺的状细胞癌.三级淋巴体结构的第三级淋巴体结构瘤微环境是一个微环境.

更多相关视频

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Author Spotlight: A Model to Study the Systemic and Local Dynamics of CD8+ T Cells During LN Metastasis

Author Spotlight: A Model to Study the Systemic and Local Dynamics of CD8⁺ T Cells During LN Metastasis

Published on: January 26, 2024

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.